Bacterial toxins

Starting its Industrial Investment in Biotech Companies, China Medical System (0867.HK) has Accelerated its Flywheel of Innovation

Retrieved on: 
Monday, April 26, 2021
Bacterial toxins, Hemolysin

This collaboration marks the beginning of the CMS\'s industrial investment in cutting-edge biotech companies.\n1.

Key Points: 
  • This collaboration marks the beginning of the CMS\'s industrial investment in cutting-edge biotech companies.\n1.
  • This product neutralizes the alpha-hemolysin (Hla) released by SA to avoid immune downregulation to B cells and to improve immune response.
  • In contrast, CMS\' industrial investment is a more advanced version of the VIC model, in which the leading party is CMS.
  • Trade at your own risk.\nSource: China Medical System Holdings Ltd.\nCopyright 2021 ACN Newswire .

Clostridium Difficile Tests Market Analysis & Forecast Model 2015-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 26, 2020
Biotechnology, Hospitals, Health, Clostridiaceae, Gram-positive bacteria, Microbiology, Medical specialties, Bacteriology, Clostridium, Pathogenic bacteria, Clostridioides difficile, Bacterial toxins

The "Clostridium Difficile Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clostridium Difficile Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.
  • This market model discusses in detail the impact of COVID-19 on Clostridium difficile Tests market for the year 2020 and beyond.
  • Key Inclusions of the market model are:
    Currently marketed Clostridium difficile Tests and evolving competitive landscape.
  • Annualized total Clostridium difficile Tests market revenue by segment and market outlooks from 2015-2030.

Analysis on Impact of COVID-19- Global Clostridium Difficile Treatment Market 2020-2024 | Evolving Opportunities With Astellas Pharma Inc. and AstraZeneca Plc | Technavio

Retrieved on: 
Tuesday, August 25, 2020
Infectious diseases, Pharmaceutical, Health, Clostridiaceae, Gram-positive bacteria, Microbiology, Medical specialties, Bacteriology, Clostridium, Pathogenic bacteria, Clostridioides difficile, Bacterial toxins

The global clostridium difficile treatment market size is expected to grow by USD 159.87 million as per Technavio.

Key Points: 
  • The global clostridium difficile treatment market size is expected to grow by USD 159.87 million as per Technavio.
  • In addition, the development of novel therapies is anticipated to boost the growth of the Clostridium Difficile Treatment Market.
  • The tentative approval of late stage molecules is one of the key factors driving the growth of the market.
  • Major Five Clostridium Difficile Treatment Companies:
    Astellas Pharma Inc. operates through a single business segment where it manufactures and sells pharmaceutical products.

New Strategy Emerges for Vaccine Against Methicillin-Resistant Staphylococcal aureus

Retrieved on: 
Tuesday, June 30, 2020
Medical specialties, Medicine, Immunology, Vaccination, Immune system, Vaccine, Vaccines, Bacterial toxins, Staphylococcus aureus, Panton–Valentine leukocidin

The new vaccination strategy, developed by researchers at NYU Grossman School of Medicine, targets toxic molecules released by all Staphylococcal bacteria, called leukocidins, rather than directly targeting the bacteria.

Key Points: 
  • The new vaccination strategy, developed by researchers at NYU Grossman School of Medicine, targets toxic molecules released by all Staphylococcal bacteria, called leukocidins, rather than directly targeting the bacteria.
  • Attempts to develop a Staphylococcal vaccine have so far failed, researchers say, in part because leukocidins kill immune system cells, or leukocytes, needed by the immune system to fight the infection and whose production is triggered by a vaccine.
  • "This strategy is based on maximum disarmament of the bacterium's ability to kill all types of immune system cells."
  • Torres says a "foolproof" vaccine against the bacteria, including MRSA, will likely involve targeting more than just its leukocidin toxins.

ALPHAEON Corporation Completes Reorganization to Simplify its Corporate Structure

Retrieved on: 
Friday, January 10, 2020
Biotechnology, General Health, Pharmaceutical, Health, Drugs, Bacterial toxins, Neurotoxins, Toxins, Botulism, Botulinum toxin, Tetanospasmin

ALPHAEON Corporation (ALPHAEON), announced today that it has completed a reorganization to simplify its corporate structure.

Key Points: 
  • ALPHAEON Corporation (ALPHAEON), announced today that it has completed a reorganization to simplify its corporate structure.
  • ALPHAEON has been renamed AEON Biopharma, Inc. (AEON), which will now focus on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, as a therapeutic application for debilitating medical conditions.
  • We continue to have a positive outlook on the long-term potential of the position held in Evolus for our stockholders.
  • AEON Biopharma, Inc. (previously known as ALPHAEON Corporation) focuses on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, for debilitating medical conditions.

The Truth Behind What's Actually Living On Our Favourite Statues…

Retrieved on: 
Friday, August 30, 2019
Medical specialties, Medicine, RTT, Infectious diseases, Conjunctivitis, Measles, Urinary tract infection, Bacterial diseases, Bacterial toxins

Statues included London's famous Lions in Trafalgar Square, the Oscar Wilde statue by Charing Cross and the famous Juliet Capulet statue in Verona.

Key Points: 
  • Statues included London's famous Lions in Trafalgar Square, the Oscar Wilde statue by Charing Cross and the famous Juliet Capulet statue in Verona.
  • With the summer holidays now in full swing, these statues will become some of Europe's major tourist attractions, drawing crowds of people from all over the world.
  • Some of the bacteria detected, such as Staphylococcus, can be potentially dangerous and can lead to infections including sepsis, conjunctivitis, cystitis as well as endocarditis.
  • Another potentially life-threatening bacteria lurking on the monuments isPseudomonas, which may cause folliculitis and ear canal infections.

The Truth Behind What's Actually Living On Our Favourite Statues…

Retrieved on: 
Friday, August 30, 2019
Medical specialties, Medicine, RTT, Infectious diseases, Conjunctivitis, Measles, Urinary tract infection, Bacterial diseases, Bacterial toxins

Statues included London's famous Lions in Trafalgar Square, the Oscar Wilde statue by Charing Cross and the famous Juliet Capulet statue in Verona.

Key Points: 
  • Statues included London's famous Lions in Trafalgar Square, the Oscar Wilde statue by Charing Cross and the famous Juliet Capulet statue in Verona.
  • With the summer holidays now in full swing, these statues will become some of Europe's major tourist attractions, drawing crowds of people from all over the world.
  • Some of the bacteria detected, such as Staphylococcus, can be potentially dangerous and can lead to infections including sepsis, conjunctivitis, cystitis as well as endocarditis.
  • Another potentially life-threatening bacteria lurking on the monuments isPseudomonas, which may cause folliculitis and ear canal infections.

US Clostridium Difficile-Associated Diarrhoea Market and Competitive Landscape, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 2, 2019
Health, Pharmaceutical, Bacteria, Clostridiaceae, Gram-positive bacteria, Microorganisms, Organisms, Antibiotic-resistant bacteria, Clostridioides difficile, Clostridium, Bacterial toxins, Clostridium difficile toxin A

The "US Clostridium Difficile-Associated Diarrhea Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Clostridium Difficile-Associated Diarrhea Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • The latest research, US Clostridium Difficile-Associated Diarrhoea Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Clostridium Difficile-Associated Diarrhoea pipeline products, Clostridium Difficile-Associated Diarrhoea epidemiology, Clostridium Difficile-Associated Diarrhoea market valuations and forecast, Clostridium Difficile-Associated Diarrhoea drugs sales and competitive landscape in the US.
  • Clostridium Difficile-Associated Diarrhoea pipeline: Find out the products in clinical trials for the treatment of Clostridium Difficile-Associated Diarrhoea by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Clostridium Difficile-Associated Diarrhoea drugs: Identify key products marketed and prescribed for Clostridium Difficile-Associated Diarrhoea in the US, including trade name, molecule name, and company
    Clostridium Difficile-Associated Diarrhoea drugs sales: Find out the sales revenues of Clostridium Difficile-Associated Diarrhoea drugs in the US
    Clostridium Difficile-Associated Diarrhoea market valuations: Find out the market size for Clostridium Difficile-Associated Diarrhoea drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Clostridium Difficile-Associated Diarrhoea drugs market share: Find out the market shares for key Clostridium Difficile-Associated Diarrhoea drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Clostridium Difficile-Associated Diarrhoea products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190702005273/en/

Global Staphylococcal Infection Drugs Market 2019-2023 | Improved Screening of Antibiotic-Resistant Strains to Boost Growth | Technavio

Retrieved on: 
Friday, May 17, 2019
Health, Infectious diseases, Pharmaceutical, Bacterial toxins, Staphylococcaceae, Epidemiology, Infection, Antibiotic, Staphylococcal infection, Macrolide, Market research

View the full release here: https://www.businesswire.com/news/home/20190517005207/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190517005207/en/
    Technavio has published a new market research report on the global staphylococcal infection drugs market from 2019-2023.
  • (Graphic: Business Wire)
    A key factor driving the growth of the global staphylococcal infection drugs market is the rise in the use of antibiotics.
  • This global staphylococcal infection drugs market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
  • Global staphylococcal infection drugs market: Segmentation analysis
    This market research report segments the global staphylococcal infection drugs market by product (beta-lactams, peptides, quinolones, macrolides, and others) and geographic regions (North America, Europe, Asia, and ROW).

The staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023

Retrieved on: 
Monday, May 13, 2019
Bacterial toxins, Epidemiology, Infection, Staphylococcal infection, Bacterial diseases, Medical specialties, Gram-positive bacteria

Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection.

Key Points: 
  • Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection.
  • Analysts have predicted that the staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023.
  • For the detailed list of factors that will drive and challenge the growth of the staphylococcal infection drugs market during the 2019-2023, view our report.
  • Factors such as the increasing incidence of staphylococcal infections and special drug designations, will provide considerable growth opportunities to staphylococcal infection drugs manufactures.